Allianz Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Allianz Asset Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-55,000	Closed	-$2.25M	–	2317
2024 Q2	$2.25M	Sell	55,000 -89,400	-62%	-$3.72M	﹤0.01%	1270
2024 Q1	$6.1M	Hold	144,400	–	–	0.01%	800
2023 Q4	$6.12M	Buy	+144,400	New	+$4.15M	0.01%	844
2022 Q3	–	Sell	-28,220	Closed	-$746K	–	2173
2022 Q2	$746K	Buy	28,220 +2,360	+9%	+$67K	﹤0.01%	1775
2022 Q1	$905K	Buy	25,860 +5,600	+28%	+$164K	﹤0.01%	1892
2021 Q4	$657K	Buy	+20,260	New	+$715K	﹤0.01%	2092

Other funds holding CERE

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Allianz Asset Management's CERE Position: Q3 2024 in Review

Allianz Asset Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 55,000 shares — an estimated $2.25M sold.

Allianz Asset Management first reported a position in CERE in Q4 2021 and held it in 6 quarters. The position peaked at $6.12M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Allianz Asset Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Allianz Asset Management sold 55,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $2.25M.
Allianz Asset Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Allianz Asset Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $6.12M in Q4 2023.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Allianz Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.